Why not?
"Melbourne, Australia; April 30, 2020; and New York, USA; April 29, 2020: Mesoblast Limited (ASX:MSB;
Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3
randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy
remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to
COVID-19 has commenced enrollment. "
The trial is specifically for "survival benefit in moderate/severe acute respiratory distress syndrome (ARDS)" and once proven, it wouldn't be too hard to change the "due to" aspect.
Confirmation Bias, page-75
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.030(2.71%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.14 | $1.08 | $2.428M | 2.202M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 108694 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 112115 | 14 |
View Market Depth
| Last trade - 13.55pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |